LabCorp Commends CDC for Revised HCV Testing Guidelines; Leading HCV Tests Available Through Monogram Biosciences, part of LabCorp’s Specialty Testing Group

BURLINGTON, N.C. -- (BUSINESS WIRE) -- Aug. 17, 2012 -- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announces its support for guidance issued today by the Centers for Disease Control and Prevention (CDC) that recommends hepatitis C virus (HCV) testing in all people born

LabCorp Completes and Publishes a Clinical Study for the Development and Validation of a PCR Assay for the Diagnosis of Bacterial Vaginosis

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 7, 2012-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the publication in the July 2012 Journal of Clinical Microbiology of a clinical study that supports validation of a new clinical diagnostic test for bacterial

LabCorp Addresses Rumors of Buyout

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 1, 2012-- Laboratory Corporation of America® Holdings (NYSE: LH) today announced it is aware of the recent reports regarding possible plans by private equity firms to seek to effect a leveraged buyout of the Company.

LabCorp Completes Acquisition of MEDTOX

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 1, 2012-- Laboratory Corporation of America® Holdings (NYSE: LH) today announced the completion of its acquisition of MEDTOX Scientific, Inc. (NASDAQ: MTOX), effective July 31, 2012 . At a special meeting held on July 31, 2012 , MEDTOX’s stockholders

Laboratory Corporation of America® Holdings Announces 2012 Second Quarter Results

LabCorp Reports Q2 Diluted EPS of $1.56 and Adjusted EPS Excluding Amortization of $1.77 , up 7.9% BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 19, 2012-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced results for the quarter ended June 30, 2012 .

LabCorp’s Acquisition of MEDTOX Clears Antitrust Approval

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 13, 2012-- Laboratory Corporation of America® Holdings (NYSE: LH) today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 2, 2012-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp to Offer Age-Based Guideline Initiative for Cervical Cancer and STD Screening

BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 14, 2012-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the launch of an innovative age-based test protocol that aids physicians when ordering cervical cancer and sexually transmitted disease (STD) screening tests.

LabCorp Announces Agreement to Acquire MEDTOX Scientific

BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 4, 2012-- Laboratory Corporation of America ® Holdings (NYSE: LH) and MEDTOX Scientific, Inc. (NASDAQ: MTOX), a provider of high quality specialized laboratory testing services and on-site/point-of-collection testing (POCT) devices, today announced that they

LabCorp is Scheduled to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--May. 8, 2012-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that David P. King , Chairman and Chief Executive Officer, is scheduled to speak at the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas, NV.